AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-11-11 11:07:462019-11-11 13:01:23AstraZeneca succeeds in treating lupus in late-stage study
